{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:42:17Z","timestamp":1761100937782},"reference-count":14,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2007,7,6]],"date-time":"2007-07-06T00:00:00Z","timestamp":1183680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2007,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aimed to evaluate the efficacy of a nonmyeloablative conditioning consisting of fludarabine and TBI in patients aged \u226560 years.A total of 32 patients (median age 62 years; range 60\u201370) with hematological malignancies were treated with fludarabine (30 mg\/m<jats:sup>2<\/jats:sup> \u00d7 3\u20135 days) and 200 cCy TBI followed by allogeneic hematopoietic stem cell transplantation (HSCT) from a matched\u2010sibling donor. GVHD prophylaxis consisted of cyclosporine and mycophenolate. Neutrophil recovery occurred in all patients at a median time of 16 days (range 9\u201334). Six patients did not become granulocytopenic. On day +30, 10 patients had &gt;95% donor chimerism and 19 patients had mixed chimerism. The cumulative probabilities of Grade II\u2013IV acute GVHD and chronic GVHD were 48 and 83%, respectively. Transplant\u2010related mortality at 100 days and 1 year was 6 and 10%, respectively. The probabilities of 2\u2010year overall (OS) and progression\u2010free survival (PFS) were 39 and 35%, respectively. The estimated 2\u2010year probability of OS and PFS for patients in early disease stages were 77 and 64%, respectively, which were significantly higher than the survival and PFS estimates of 0% obtained in patients with advanced disease stages at the time of transplant. Our analysis would suggest that for patients older than 60, this regimen is well tolerated and associated with a low incidence of transplant\u2010related mortality. The leukemic burden at time of transplant has proven to be the most important risk factor for the outcome. Am. J. Hematol. 82:863\u2013866, 2007. \u00a9 2007 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.20990","type":"journal-article","created":{"date-parts":[[2007,7,6]],"date-time":"2007-07-06T14:51:01Z","timestamp":1183733461000},"page":"863-866","source":"Crossref","is-referenced-by-count":20,"title":["Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: Results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial"],"prefix":"10.1002","volume":"82","author":[{"given":"Michele","family":"Falda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Busca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ileana","family":"Baldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Mordini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardino","family":"Allione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Morello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Narni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella","family":"Santarone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Bacigalupo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,7,6]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.806"},{"key":"e_1_2_1_3_2","first-page":"618a","article-title":"Haematopoietic precursor cell transplants, main risk factors","volume":"86","author":"Gratwohl A","year":"1995","journal-title":"Blood"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.110"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704540"},{"key":"e_1_2_1_6_2","first-page":"742a","article-title":"Nonmyeloablative hematopoietic stem cell transplants (HSCT) from HLA\u2010matched related donors for patients with hematologic malignancies: Clinical results of a TBI\u2010based conditioning regimen","volume":"98","author":"Sandmaier BM","year":"2001","journal-title":"Blood"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.06.006"},{"key":"e_1_2_1_8_2","first-page":"852","article-title":"A non\u2010myeloablative conditioning regimen in allogeneic stem cell transplantation from related and unrelated donors in elderly patients","volume":"91","author":"Tsirigotis P","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403591"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.694"},{"key":"e_1_2_1_11_2","first-page":"127","article-title":"Myeloablative allogeneic hematopoietic stem cell transplantation in elderly patients","volume":"10","author":"Ditschkowski M","year":"2005","journal-title":"Clin Transplant"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-197410000-00001"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90380-0"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.20990","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.20990","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T05:56:09Z","timestamp":1700027769000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.20990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,6]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["10.1002\/ajh.20990"],"URL":"https:\/\/doi.org\/10.1002\/ajh.20990","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,6]]}}}